Literature DB >> 29555182

Induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A systematic review and meta-analysis.

Teng Hwee Tan1, Yu Yang Soon1, Timothy Cheo2, Francis Ho1, Lea Choung Wong1, Jeremy Tey1, Ivan W K Tham1.   

Abstract

PURPOSE: To determine if the addition of induction chemotherapy (IC) to concurrent chemoradiation (CCRT) in locally advanced nasopharyngeal carcinoma (LA-NPC) can improve survival.
METHODS: We performed a meta-analysis of both randomized controlled trials (RCTs) and observational studies (OBS) to compare the effects of addition of IC to CCRT versus (vs) CCRT alone on overall survival (OS), progression free survival (PFS), distant metastasis-free survival (DMFS) and adverse events (AE) in LA-NPC. We searched MEDLINE for eligible studies comparing IC plus CCRT vs CCRT for LA-NPC from Jan 1996 to May 2017. We selected RCTs and OBS that included patients with non-metastatic, LA-NPC who received IC followed by CCRT or CCRT alone. Three reviewers independently assessed the abstracts for eligibility. We assessed the methodological quality of the included studies using the MERGE criteria. We performed the meta-analysis with random effects model. We used the GRADE approach to appraise the quality of evidence from RCTs. The primary outcome was OS; secondary outcomes included PFS, DMFS and AE.
RESULTS: We found six RCTs and five OBS including 2802 patients with low to moderate risk of bias in their methodological quality. There was high quality evidence from the RCTs that IC improved PFS (HR 0.69, 95% CI 0.57-0.84, P = 0.0003, I2 = 0%) and OS (HR 0.77, 95% CI 0.60-0.98, P = 0.03, I2 = 0%) significantly and was associated with more frequent AE. The estimates of IC effects from RCTs and OBS were similar (PFS HR 0.69 vs 0.71, interaction P (IP) = 0.92; OS HR 0.77 vs 0.58, IP = 0.27).
CONCLUSIONS: IC delays disease progression and improves survival significantly for LA-NPC treated with CCRT, and was associated with more toxicity. There were no divergent results between RCTs and OBS. IC followed by CCRT can be considered one of the standard treatment options for LA-NPC.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Concurrent chemoradiation; Induction chemotherapy; Nasopharyngeal carcinoma

Mesh:

Year:  2018        PMID: 29555182     DOI: 10.1016/j.radonc.2018.02.027

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  21 in total

Review 1.  Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.

Authors:  Lucheng Fang; Licai Shi; Wen Wang; Tingting Hu; Xingwang Rao
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-17       Impact factor: 2.503

2.  A challenging presentation of invasive nasopharyngeal sarcomatoid carcinoma.

Authors:  Alexander Yao; Haroon Saeed; Gavin Udall; Vivek Kaushik; Lip Wai Lee
Journal:  BMJ Case Rep       Date:  2019-07-08

3.  A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma.

Authors:  Pu-Yun OuYang; Xiao-Min Zhang; Xing-Sheng Qiu; Zhi-Qiao Liu; Lixia Lu; Yuan-Hong Gao; Fang-Yun Xie
Journal:  Oncologist       Date:  2019-02-19

4.  Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients.

Authors:  Pierre Blanchard; Anne W M Lee; Alexandra Carmel; Ng Wai Tong; Jun Ma; Anthony T C Chan; Ruey Long Hong; Ming-Yuan Chen; Lei Chen; Wen-Fei Li; Pei-Yu Huang; Dora L W Kwong; Sharon S X Poh; Roger Ngan; Hai-Qiang Mai; Camille Ollivier; George Fountzilas; Li Zhang; Jean Bourhis; Anne Aupérin; Benjamin Lacas; Jean-Pierre Pignon
Journal:  Clin Transl Radiat Oncol       Date:  2021-11-26

Review 5.  Nasopharyngeal carcinoma: an evolving paradigm.

Authors:  Kenneth C W Wong; Edwin P Hui; Kwok-Wai Lo; Wai Kei Jacky Lam; David Johnson; Lili Li; Qian Tao; Kwan Chee Allen Chan; Ka-Fai To; Ann D King; Brigette B Y Ma; Anthony T C Chan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-30       Impact factor: 66.675

Review 6.  Current Role of Chemotherapy in Nonmetastatic Nasopharyngeal Cancer.

Authors:  Tapesh Bhattacharyya; Geethu Babu; Cessal Thommachan Kainickal
Journal:  J Oncol       Date:  2018-10-01       Impact factor: 4.375

7.  Outcomes of Adding Induction Chemotherapy to Concurrent Chemotherapy for Nasopharyngeal Carcinoma Patients with Moderate-Risk in the Intensity-Modulated Radiotherapy Era.

Authors:  Zhen Su; Guo-Rong Zou; Jie Tang; Xiu Yue Li; Fang-Yun Xie
Journal:  Ther Clin Risk Manag       Date:  2020-03-26       Impact factor: 2.423

8.  The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis.

Authors:  Bi-Cheng Wang; Bo-Ya Xiao; Guo-He Lin; Chang Wang; Quentin Liu
Journal:  BMC Cancer       Date:  2020-05-06       Impact factor: 4.430

9.  Induction Chemotherapy Improved Long Term Outcomes in Stage IV Locoregional Advanced Nasopharyngeal Carcinoma.

Authors:  Yu-Wen Wang; Sheng-Yow Ho; Sung-Wei Lee; Chia-Chun Chen; Shieh Litsu; Wen-Tsung Huang; Ching-Chieh Yang; Chia-Hui Lin; Hsuan-Yu Chen; Li-Ching Lin
Journal:  Int J Med Sci       Date:  2020-02-10       Impact factor: 3.738

10.  Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.

Authors:  Wang Fangzheng; Jiang Chuner; Qin Haiyan; Sun Quanquan; Ye Zhimin; Liu Tongxin; Liu Jiping; Wu Peng; Shi Kaiyuan; Fu Zhenfu; Jiang Yangming
Journal:  Medicine (Baltimore)       Date:  2019-12       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.